Please assess the completion status of the following clinical trial:

Trial Title: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation~* Men and women aged ≥ 25 - 80 (included) years of age~* Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline~* Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP) for respiratory failure~* Confirmed infection with COVID-19 by any acceptable test available/ utilized at each site~* Patient with medical insurance or government support~Exclusion Criteria:~* Pregnancy or breast feeding;~* Refusal or inability to practice contraception regardless of the gender of the patient;~* ALT and/or AST \> 5 x ULN~* Known, active auto-immune disease;~* Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing;~* Patients with past history of Solid Organ transplant.~* Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load.~* Patients whose respiratory condition is showing significant deterioration as indicated by:~  * 8a requirement for an increase in inspired oxygen concentrations of 20% or more over the past 24 hours to maintain SpO2 at greater than or equal to 88%~ * 8b or need for invasive mechanical ventilation~* Patients showing an increase of the NEWS2 score by more than 6 points during the screening / baseline period (48 to 72 hrs prior to first administration)~* Patients with chronic kidney dialysis~* Patients with a SOFA score ≥ 9 at baseline~* Patients with a BMI \> 40~* Patients receiving any agent with immune suppressive effects,such as anti-IL6 treatments like Tocilizumab or Sarilumab which should preferably be minimized~* Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) \< 1.5x109/L, Platelets \< 50,000 per mm3~* Patients with uncontrolled pre-existing severe major organ dysfunction (cardiac, liver or renal failure)~* Vaccination with live attenuated vaccines in the month preceding the inclusion~* Use of chronic oral corticosteroids ≥ 10mg prednisone equivalent a day for a non-COVID-19 related condition~* Patients with baseline Rockwood Clinical Frailty Scale ≥ 6.~* Patients with known hypersensitivity to natural or recombinant Interleukin-7 or to any of the excipients~* Patients under guardianship

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYT107 (Type: EXPERIMENTAL): Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
- Saline (Type: PLACEBO_COMPARATOR): Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations

Based on this trial design, predict the completion outcome and termination type (if applicable).